3',3'''-BiapigeninCAS# 151455-26-4 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
Cas No. | 151455-26-4 | SDF | Download SDF |
PubChem ID | N/A | Appearance | Yellow powder |
Formula | C30H18O10 | M.Wt | 538.5 |
Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
3',3'''-Biapigenin Dilution Calculator
3',3'''-Biapigenin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.857 mL | 9.2851 mL | 18.5701 mL | 37.1402 mL | 46.4253 mL |
5 mM | 0.3714 mL | 1.857 mL | 3.714 mL | 7.428 mL | 9.2851 mL |
10 mM | 0.1857 mL | 0.9285 mL | 1.857 mL | 3.714 mL | 4.6425 mL |
50 mM | 0.0371 mL | 0.1857 mL | 0.3714 mL | 0.7428 mL | 0.9285 mL |
100 mM | 0.0186 mL | 0.0929 mL | 0.1857 mL | 0.3714 mL | 0.4643 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Ochnaflavone
Catalog No.:BCN0703
CAS No.:50276-96-5
- Shanciol B
Catalog No.:BCN0702
CAS No.:208106-53-0
- 5,6-Dihydroxy-7,8-dimethoxyflavone
Catalog No.:BCN0701
CAS No.:76844-65-0
- Delicaflavone
Catalog No.:BCN0700
CAS No.:343569-15-3
- Luteolin 5-methyl ether
Catalog No.:BCN0699
CAS No.:58115-29-0
- Violanone
Catalog No.:BCN0698
CAS No.:52250-38-1
- Luteolin 5,3'-dimethyl ether
Catalog No.:BCN0697
CAS No.:62346-14-9
- (2S)-Pinocembrin 7-O-[2''-O-(5'''-O-trans-cinnamoyl)-β-D-apiofuranosyl]-β-D-glucoside
Catalog No.:BCN0696
CAS No.:773899-29-9
- Kayaflavone
Catalog No.:BCN0695
CAS No.:481-45-8
- E,Z-Platanoside
Catalog No.:BCN0694
CAS No.:1197343-17-1
- Quercetin 4'-O-galactoside
Catalog No.:BCN0693
CAS No.:381728-34-3
- Tamarixin
Catalog No.:BCN0692
CAS No.:27542-39-8
- Chrysocauloflavone I
Catalog No.:BCN0705
CAS No.:899789-51-6
- 6,7,4'-Trihydroxyflavanone
Catalog No.:BCN0706
CAS No.:189689-31-4
- Procyanidin B2 3,3'-di-O-gallate
Catalog No.:BCN0707
CAS No.:79907-44-1
- 2'',3''-Dihydro-3',3'''-biapigenin
Catalog No.:BCN0708
CAS No.:151455-25-3
- 3',3'''-Binaringenin
Catalog No.:BCN0709
CAS No.:145399-99-1
- 2'',3''-Dihydroochnaflavone
Catalog No.:BCN0710
CAS No.:340997-02-6
- Procyanidin B5
Catalog No.:BCN0711
CAS No.:12798-57-1
- Procyanidin B2 3''-O-gallate
Catalog No.:BCN0712
CAS No.:73086-04-1
- 2"-O-Glucosylrutin
Catalog No.:BCN0713
CAS No.:55696-55-4
- 2,3-Dihydroamentoflavone
Catalog No.:BCN0714
CAS No.:34340-51-7
- Procyanidin B-5 3,3'-di-O-gallate
Catalog No.:BCN0715
CAS No.:106533-60-2
- Quercetin dimer
Catalog No.:BCN0716
CAS No.:167276-19-9
Improved solubility, dissolution rate, and oral bioavailability of main biflavonoids from Selaginella doederleinii extract by amorphous solid dispersion.[Pubmed:32037895]
Drug Deliv. 2020 Dec;27(1):309-322.
Amentoflavone, robustaflavone, 2'',3''-dihydro-3',3'''-biapigenin, 3',3'''-binaringenin, and delicaflavone are five major hydrophobic components in the total biflavonoids extract from Selaginella doederleinii (TBESD) that display favorable anticancer properties. The purpose of this study was to develop a new oral delivery formulation to improve the solubilities, dissolution rates, and oral bioavailabilities of the main ingredients in TBESD by the solid dispersion technique. Solid dispersions of TBESD with various hydrophilic polymers were prepared, and different technologies were applied to select the suitable carrier and method. TBESD amorphous solid dispersion (TBESD-ASD) with polyvinylpyrrolidone K-30 was successfully prepared by the solvent evaporation method. The physicochemical properties of TBESD-ASD were investigated by scanning electron microscopy, differential scanning calorimetry, and Fourier-transform infrared spectroscopy. As a result, TBESD was found to be molecularly dispersed in the amorphous carrier. The solubilities and dissolution rates of all five ingredients in the TBESD-ASD were significantly increased (nearly 100% release), compared with raw TBESD. Meanwhile, TBESD-ASD showed good preservation stability for 3 months under accelerated conditions of 40 degrees C and 75% relative humidity. A subsequent pharmacokinetic study in rats revealed that Cmax and AUC0-t of all five components were significantly increased by the solid dispersion preparation. An in vivo study clearly revealed that compared to raw TBESD, a significant reduction in tumor size and microvascular density occurred after oral administration of TBESD-ASD to xenograft-bearing tumor mice. Collectively, the developed TBESD-ASD with the improved solubility, dissolution rates and oral bio-availabilities of the main ingredients could be a promising chemotherapeutic agent for cancer treatment.
Proliposomes for oral delivery of total biflavonoids extract from Selaginella doederleinii: formulation development, optimization, and in vitro-in vivo characterization.[Pubmed:31692515]
Int J Nanomedicine. 2019 Aug 20;14:6691-6706.
Purpose: Amentoflavone, robustaflavone, 2'',3''-dihydro-3',3'''-biapigenin, 3',3'''-binaringenin and delicaflavone are five major active ingredients in the total biflavonoids extract from Selaginella doederleinii (TBESD) with favorable anticancer properties. However, the natural-derived potent antitumor agent of TBESD is undesirable due to its poor solubility. The present study was to develop and optimize a proliposomal formulation of TBESD (P-TBESD) to improve its solubility, oral bioavailability and efficacy. Materials and methods: P-TBESD containing a bile salt, a protective hydrophilic isomalto-oligosaccharides (IMOs) coating, were successfully prepared by thin film dispersion-sonication method. The physicochemical and pharmacokinetic properties of P-TBESD were characterized, and the antitumor effect was evaluated using the HT-29 xenograft-bearing mice models in rats. Results: Compared with TBESD, the relative bioavailability of amentoflavone, robustaflavone, 2'',3''-dihydro-3',3'''-biapigenin, 3',3'''-binaringenin and delicaflavone from P-TBESD were 669%, 523%, 761%, 955% and 191%, respectively. The results of pharmacodynamics demonstrated that both TBESD and P-TBESD groups afforded antitumor effect without systemic toxicity, and the antitumor effect of P-TBESD was significantly superior to that of raw TBESD, based on the tumor growth inhibition and histopathological examination. Conclusion: Hence, IMOs-modified proliposomes have promising potential for TBESD solving the problem of its poor solubility and oral bioavailability, which can serve as a practical oral preparation for TBESD in the future cancer therapy.